Sign up to save your podcasts
Or
Share Meeting Future Global Challenges: Case-Based Presentations in the Management of NSCLC
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Meeting Future Global Challenges: Case-Based Presentations in the Management of NSCLC
CME credits: 0.25
Valid until: 16-06-2022
Claim your CME credit at https://reachmd.com/programs/cme/meeting-future-global-challenges-case-based-presentations-management-nsclc/12600/
For the 3% to 4% of patients with non-small cell lung cancer (NSCLC) who harbor a MET exon 14 skipping mutation, the prognosis is grave. MET gene dysregulation may also play a role in the emergence of resistance to EGFR TKI therapy in patients with EGFR-mutated NSCLC, further complicating treatment. Join our case discussion as Dr. Paul Paik and Dr. Josh Sabari highlight the importance of identifying MET gene aberrations in patients with NSCLC.
View all episodes
By ReachMD
4.3
33 ratings
CME credits: 0.25
Valid until: 16-06-2022
Claim your CME credit at https://reachmd.com/programs/cme/meeting-future-global-challenges-case-based-presentations-management-nsclc/12600/
For the 3% to 4% of patients with non-small cell lung cancer (NSCLC) who harbor a MET exon 14 skipping mutation, the prognosis is grave. MET gene dysregulation may also play a role in the emergence of resistance to EGFR TKI therapy in patients with EGFR-mutated NSCLC, further complicating treatment. Join our case discussion as Dr. Paul Paik and Dr. Josh Sabari highlight the importance of identifying MET gene aberrations in patients with NSCLC.